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Aging and psychosocial stress are associated with increased in-
flammation and disease risk, but the underlying molecular mecha-
nisms are unclear. Because both aging and stress are also associated
with lasting epigenetic changes, a plausible hypothesis is that stress
along the lifespan could confer disease risk through epigenetic
effects on molecules involved in inflammatory processes. Here, by
combining large-scale analyses in human cohorts with experiments in
cells, we report that FKBP5, a protein implicated in stress physiology,
contributes to these relations. Across independent human cohorts
(total n > 3,000), aging synergized with stress-related phenotypes,
measured with childhood trauma and major depression question-
naires, to epigenetically up-regulate FKBP5 expression. These age/
stress-related epigenetic effects were recapitulated in a cellular
model of replicative senescence, whereby we exposed replicating
human fibroblasts to stress (glucocorticoid) hormones. Unbiased
genome-wide analyses in human blood linked higher FKBP5 mRNA
with a proinflammatory profile and altered NF-κB–related gene net-
works. Accordingly, experiments in immune cells showed that higher
FKBP5 promotes inflammation by strengthening the interactions of
NF-κB regulatory kinases, whereas opposing FKBP5 either by genetic
deletion (CRISPR/Cas9-mediated) or selective pharmacological inhibi-
tion prevented the effects on NF-κB. Further, the age/stress-related
epigenetic signature enhanced FKBP5 response to NF-κB through a
positive feedback loop and was present in individuals with a his-
tory of acute myocardial infarction, a disease state linked to pe-
ripheral inflammation. These findings suggest that aging/stress-
driven FKBP5–NF-κB signaling mediates inflammation, potentially
contributing to cardiovascular risk, and may thus point to novel
biomarker and treatment possibilities.
aging | epigenetics | FKBP5 | inflammation | psychosocial stress
Aging is the single most important risk factor for severaldisease phenotypes that are leading causes of morbidity and
mortality (1). However, individuals of the same age exhibit
substantial variability in their risk of developing aging-related
disease (2). Among important factors influencing disease risk,
studies show that psychosocial stressors, such as childhood
trauma, as well as stress-related psychiatric disorders, including
major depressive disorder (MDD), increase risk for aging-
related diseases, most notably cardiovascular syndromes (3–7).
Significance
Diseases of the aging are the leading cause of morbidity and
mortality. Elucidating the molecular mechanisms through which
modifiable factors, such as psychosocial stress, confer risk for aging-
related disease can have profound implications. By combining
studies in humans with experiments in cells, we show that aging
and stress synergize to epigenetically upregulate FKBP5, a protein
implicated in stress physiology. Higher FKBP5 promotes in-
flammation by activating the master immune regulator NF-κB,
whereas opposing FKBP5, either genetically or pharmacologically,
prevents the effects on NF-κB. Further, the aging/stress-related
epigenetic signature of FKBP5 is associated with history of myo-
cardial infarction, a disease linked to inflammation. These findings
provide molecular insights into stress-related disease, pointing to
biomarker and treatment possibilities.
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Studies further suggest that aging and stress-related phenotypes
may together confer disease risk by increasing peripheral in-
flammation (5, 8–11), but the underlying mechanisms are
poorly understood.
Mechanistically, the effects of stress on inflammation and
disease risk could be driven by stress-responsive molecules able
to modulate immune function. A plausible such molecule to
examine is the FK506-binding protein 51 (FKBP51/FKBP5), a
protein cochaperone that is acutely induced by stress and can
influence biological processes through protein–protein interac-
tions (12–19). Interestingly, FKBP5 up-regulation has been ob-
served not only with stress exposure and glucocorticoid
stimulation but also in the aging brain (20, 21) and in some
disease phenotypes (15, 17, 20). However, it is unknown whether
aging regulates FKBP5 in the immune system and how this ef-
fect, if present, could shape risk for cardiovascular disease. Both
aging and stress can have lasting effects on the epigenome (22–
25), and FKBP5 transcription can be regulated by epigenetic
mechanisms (26–28); thus, a plausible hypothesis is that stress
exposure along the lifespan could epigenetically deregulate
FKBP5 in immune cells, potentially contributing to peripheral
inflammation and disease risk.
Here we address these questions by combining genome-wide
analyses in human cohorts with mechanistic investigations in
cells. Convergent findings support a model whereby aging and
stress-related phenotypes synergize to decrease DNA methyl-
ation at selected enhancer-related FKBP5 sites, epigenetically
up-regulating FKBP5 in whole blood and in distinct immune cell
subtypes. Higher FKBP5 in turn promotes NF-κB (nuclear factor
kappa-light-chain-enhancer of activated B cells)-driven peripheral
inflammation. Accordingly, the age/stress-related FKBP5 epige-
netic signature is present in individuals with a history of acute
myocardial infarction (MI), a disease state linked to peripheral
inflammation. We further find that the cellular effects of stress on
NF-κB are prevented by either CRISPR/Cas9 deletion of the
FKBP5 gene or a selective FKBP5 antagonist, suggesting FKBP5–
NF-κB signaling as a tractable treatment candidate. Together
these findings provide molecular insights into mechanisms linking
aging and stress with peripheral inflammation and cardiovascular
risk, thereby pointing to biomarker and intervention possibilities.
Results
FKBP5 DNA Methylation Decreases Along the Lifespan at Selected
Cytosine–Guanine Dinucleotides. DNA methylation at cytosine–
guanine dinucleotides (CpGs) can change with age (24), an ef-
fect moderated in part by environmental factors (29), including
psychosocial stress (23). These epigenetic changes can in turn
contribute to disease risk by affecting the expression of molecules
regulated by the age-related genomic sites, thus altering cell and
tissue function (25, 30). Therefore, to gain insights into the
mechanisms through which stress contributes to disease risk, it is
relevant to examine the effects of stress on age-related CpGs.
To identify such age-related FKBP5 CpGs, we used Illumina
HumanMethylation450 BeadChip (450K) data from three in-
dependent cohorts with broad age range and documented stress-
related phenotypes: the Grady Trauma Project (GTP; n = 393,
age range 18 to 77 y); the Cooperative Health Research in the
Region of Augsburg F4 community study (KORA; n = 1,727, age
range 32 to 81 y); and the Max Planck Institute of Psychiatry
cohort (MPIP; n = 537, age range 18 to 87 y) (demographics in
Dataset S1). These analyses included all available CpGs covered
by the 450K within or in close proximity (10 kb upstream or
downstream) to the FKBP5 locus (chromosome 6p21.31). After
controlling for potential confounders, including age, sex, pop-
ulation stratification, and blood cell proportions in the GTP,
KORA, and MPIP, as wells as for smoking and other available
cohort-specific covariates (see SI Appendix, Supplementary Meth-
ods for additional details), and after false discovery rate (FDR)
correction for multiple comparisons, two CpGs (cg20813374 and
cg00130530) showed consistent and robust age-related decrease in
methylation across all cohorts (detailed statistics in Dataset S2).
These two age-related sites lie in close proximity to each other
proximally upstream of the FKBP5 transcription start site (TSS;
−462 bp for cg20813374 and −484 bp for cg00130530; UCSC
Genome Browser; Dataset S2) and show significant pairwise
correlations in all cohorts (GTP: r = 0.83, P < 2.2 × 10−16; KORA:
r = 0.61, P < 2.2 × 10−16; MPIP: r = 0.37, P < 2.2 × 10−16). The
association of age with average methylation of the two CpGs is
depicted in Fig. 1A and SI Appendix, Fig. S1A. To validate this
finding with a non-hybridization-based DNA methylation method,
we performed targeted bisulfite sequencing with the Illumina
MiSeq in a smaller sample of female subjects, again observing
robust pairwise correlation of the two CpGs (r = 0.62, P = 5.7 ×
10−10) and significantly lower average methylation of the two sites
with increasing age (n = 77, P = 1.9 × 10−2; SI Appendix, Fig. S2).
Given the close proximity and consistent pairwise correlations
between the two age-related FKBP5 CpGs, all subsequent analyses
examined the average methylation level of these two sites.
Age-Related Decrease in FKBP5 Methylation Is Not Confounded by
Blood Cell Type Heterogeneity and Occurs in Purified Immune Cell
Subtypes. Peripheral blood cell counts change along the life-
span (31), raising the possibility that heterogeneity in blood cell
type composition could be confounding our results (32), despite
the consistent inverse relation we observed between aging and
FKBP5 methylation after adjustment for calculated cell types in
the regression models (Fig. 1A and Dataset S2). To rule out this
possibility, we first performed a series of sensitivity analyses in
our cohorts. The inverse relation between age and methylation
of the two FKBP5 CpGs (cg20813374 and cg00130530) was
consistent across the GTP, KORA, and MPIP cohorts (all P
values <10−7; Fig. 1A), and there was no consistent relation
between calculated blood cell subtypes (the potential con-
founder) and either age or FKBP5 methylation levels (our vari-
ables of interest), suggesting that strong confounding by cell
subtypes was not present (Dataset S3). This was further validated
using an additional dataset of male and female subjects (n = 213)
with both 450K data and differential complete blood counts;
methylation of the age-related CpGs did not significantly cor-
relate with any of the counted blood cell types (Dataset S3) and
was again robustly associated with age after adjustment for sex
and all cell types (β = −0.0077, SE = 0.0009, P = 5.2 × 10−15).
To further understand how aging influences FKBP5 methyl-
ation in specific immune cell types, we analyzed publicly avail-
able DNA methylation data in whole blood, as well as FACS-
sorted CD4 T cells and neutrophils, from male subjects with a
broad age range (33). We again observed an inverse relation
between age and methylation of the two FKBP5 CpGs in whole
blood (n = 184, r = −0.30, P = 3.6 × 10−5). Importantly, the same
effect size was present in purified CD4 T cells (n = 46, r = −0.32,
P = 3.3 × 10−2), whereas this effect was in the same direction but
nonsignificant in purified neutrophils (n = 48, r = −0.20, P =
1.7 × 10−1; SI Appendix, Fig. S3). Together, these findings show
that increasing age is associated with lower FKBP5 methylation
in T cell (and likely other distinct immune cell) subtypes and that
this effect is not solely the result of age-related changes in blood
cell type composition.
Early Life Stress and Depressive Phenotypes Accelerate the Age-
Related Decrease in FKBP5 Methylation. FKBP5 responds to stress
and glucocorticoids and can undergo decrease in DNA methyl-
ation at distinct CpGs (26–28, 34, 35). Therefore, it is plausible
that higher stress burden throughout life could induce lasting epi-
genetic changes, potentially accelerating decrease in methylation of
the two age-related FKBP5 CpGs. To investigate this hypothesis, we
examined the combined effects of age and stress-related phenotypes
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on average methylation of the two CpGs. As information on current
depressive symptoms was available in all three cohorts, we first in-
vestigated this phenotype. After adjusting for all covariates (SI
Appendix, Supplementary Methods), depressive phenotypes consis-
tently accelerated the age-related decrease in FKBP5 methylation
(total n = 2,249, meta-analysis interaction P = 2.6 × 10−2; Fig. 1B).
This association remained significant after further adjusting for
education, as a measure of socioeconomic status, in all cohorts
(meta-analysis interaction P = 3.7 × 10−2). Because early life trauma
is among the strongest risk factors for developing MDD (5), we
further examined whether the effect of depression on age-related
decrease in FKBP5 methylation is moderated by childhood trauma
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Fig. 1. Aging and stress are together associated with decreased DNA methylation at selected FKBP5 CpGs. (A) Methylation decreases at selected FKBP5 CpGs
along the human lifespan (GTP: βage = −0.0045, SE = 0.0008, P = 8 × 10−8; KORA: βage = −0.0055, SE = 0.0005, P < 2 × 10−16; MPIP: βage = −0.0064, SE = 0.0012,
P = 7 × 10−8; total n = 2,523). (B) Depressive phenotypes are associated with accelerated age-related decrease in FKBP5 methylation (total n = 2,249, meta-
analysis interaction P = 2.6 × 10−2, heterogeneity P = 2.7 × 10−1). Statistics per cohort: GTP: interaction P = 1.9 × 10−2, βage for moderate/severe depression =
−0.0075 (SE = 0.0014) vs. βage for no/mild depression = −0.0032 (SE = 0.0011); KORA: interaction P = 6.3 × 10−1, βage for higher levels of depression = −0.0063
(SE = 0.0011) vs. βage for lower levels of depression = −0.0047 (SE = 0.0007); MPIP: interaction P = 1.9 × 10−1, βage for depressed = −0.0077 (SE = 0.0015) vs. βage
for nondepressed = −0.0044 (SE = 0.0019). (C) Early life separation is associated with lower methylation of the age-related FKBP5 CpGs in the HBCS
(βseparation = −0.0932, SE = 0.0343, P = 7.4 × 10−3, mean DNA methylation difference = 1.4%). The y axis in A, B, and C depicts the residuals of the average DNA
methylation levels (M-values) of the two age-related FKBP5 CpGs (cg20813374 and cg00130530) and reported statistics are after adjustment for all covariates
for each cohort (SI Appendix, Supplementary Methods); for a more intuitive visualization, selected panels are also depicted as percent DNA methylation (Beta-
values) in SI Appendix, Fig. S1. (D) In vitro aging and exposure to the stress hormone (glucocorticoid) receptor agonist DEX additively decrease methylation at
the age-related FKBP5 CpGs in the IMR-90 fibroblast model of replicative senescence (F1,6 = 6.3, interaction P = 4.6 × 10
−2, n = 4 replicates per group).
Statistical comparisons were performed with two-way mixed-design ANOVA (per experimental design), using replicative age as the between-subject and DEX
treatment as the within-subject factor. Statistically significant effects were followed with Bonferroni-corrected pairwise comparisons, shown as follows: *P <
5 × 10−2, statistically significant pairwise comparisons for young vs. old replicative age; #P < 5 × 10−2, statistically significant pairwise comparison for vehicle vs.
DEX-treated old cells. Error bars depict the SE around the group mean. The y axis in D depicts the average percent DNA methylation of the two FKBP5 CpGs.
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severity as measured with the childhood trauma questionnaire
(CTQ) in the GTP. This stratified analysis yielded a significant age–
depression interaction in the higher-CTQ (interaction P = 4.6 × 10−2)
but not the lower-CTQ group (interaction P = 3.3 × 10−1) and no
main effect of childhood trauma severity (P = 3.7 × 10−1). Fi-
nally, to examine whether exposure to a severe and prolonged
early childhood stressor itself is associated with lasting decrease
in methylation of the age-related CpGs, we compared elderly in-
dividuals that had prolonged early life separation from their parents
with sex- and age-matched nonseparated controls in a fourth co-
hort, the Helsinki Birth Cohort Study (n = 160, age range 58 to
69 y, demographics in Dataset S1). In this cohort, early life sepa-
ration was associated with reduced methylation of the age-related
CpGs (P = 7.4 × 10−3; Fig. 1C and SI Appendix, Fig. S1B).
These findings suggest that childhood trauma and depressive
phenotypes together accelerate the age-related decrease in
FKBP5 methylation in peripheral blood.
The Effects of Both Aging and Stress on FKBP5 Methylation Are
Recapitulated in Vitro. The findings presented above identify two
FKBP5 CpGs (cg20813374 and cg00130530) that show a con-
sistent association of lower methylation levels with aging and
stress-related phenotypes; however, these findings are inherently
limited by the use of human subjects where experimental ma-
nipulation is not feasible. To experimentally support these as-
sociations, we used a cellular model of replicative senescence
(IMR-90 fibroblasts) to test whether replicative aging and
stress―which is commonly modeled in the dish with the stress
(glucocorticoid) hormone receptor agonist dexamethasone
(DEX) (26, 36)―influences FKBP5 methylation at these sites.
Population doubling level (PDL) was calculated as previously
(37), and FKBP5 methylation was measured with targeted bi-
sulfite pyrosequencing and compared between cells of young
(PDL = 22) and old (PDL = 42) replicative age treated for 7 d
with either vehicle (DMSO) or 100 nM DEX. In accordance with
our in vivo findings, in vitro aging and DEX additively decreased
DNA methylation at the two FKBP5 CpGs (interaction P = 4.6 ×
10−2, DNA methylation decrease in old vs. young cells = 10.1%,
and additional methylation decrease in old cells treated with
DEX vs. vehicle = 3.4%; Fig. 1D). Together with our observa-
tions in human cohorts (Fig. 1 A–C), these convergent findings
show that aging and stress may influence FKBP5 methylation
across different cohorts, distinct cell types, and contexts.
Decreased Methylation at the Age/Stress-Related FKBP5 CpGs Is
Associated with FKBP5 Up-Regulation in Peripheral Blood. DNA
methylation patterns can shape gene expression, thereby con-
tributing to cellular function and phenotypic expression (38, 39).
The age/stress-related FKBP5 CpGs identified above lie proxi-
mally (<500 bp) upstream of the TSS for all highly expressed
isoforms of FKBP5 and are intronic only for the minimally
expressed variant 2 of the gene (UCSC Genome Browser, UCSC
Gens Track; GTEx portal). Integrative analysis of chromatin
states using ChromHMM (40) showed that the two CpGs
colocalize with signatures that are consistent with either en-
hancers or flanking active TSS in a large number of cell types
(Dataset S4). In immune cells, the CpGs are commonly mapped
to either an enhancer or flanking active TSS (SI Appendix, Fig.
S4). Further, in most cell types the two sites show intermediate
levels of methylation and colocalize with H3K4me1 and
H3K27me3 signatures (Roadmap Epigenome Browser; shown
for immune cell proxy in SI Appendix, Fig. S5). This landscape is
most consistent with a poised enhancer (41) that upon tran-
scription factor binding could interact and regulate the down-
stream FKBP5 TSS.
To examine whether DNA methylation of these CpGs influ-
ences gene transcription, we used FKBP5mRNA data measured in
the GTP cohort with Illumina HumanHT-12 Expression BeadChip
arrays (n = 355). DNA methylation levels of the age/stress-related
sites were inversely associated with FKBP5 mRNA levels (P =
1.6 × 10−2; Fig. 2A). We found similar negative correlations in
publicly available data from breast tissue samples of control female
subjects (n = 84, r = −0.26, P = 1.6 × 10−2; SI Appendix, Fig. S6)
(42). Since FKBP5 transcription is robustly induced by glucocor-
ticoids (28, 43) and given that the CpGs are located in predicted
poised enhancers (SI Appendix, Fig. S5), we speculated that
methylation at the age/stress-related FKBP5 CpGs could moderate
the effect of cortisol on FKBP5 levels. After confirming a robust
positive correlation between cortisol and FKBP5 mRNA (r = 0.41,
P = 1 × 10−12), we found that the cortisol–FKBP5 relationship was
significantly stronger in individuals with below- compared with
above-median methylation levels in the GTP (interaction P = 1.4 ×
10−3; Fig. 2B). In addition, the phenotypes associated with lower
methylation levels moderated the relationship between cortisol
and FKBP5 mRNA; specifically, this relationship was significantly
stronger in older subjects as defined with a median split of age
(interaction P = 2.4 × 10−5; Fig. 2C) and in individuals with higher
severity of depression and childhood trauma (interaction P = 7.3 ×
10−5; Fig. 2D). These findings are in line with previous observa-
tions that stressors can induce lasting epigenetic effects on other
sites of the FKBP5 locus (26–28) and suggest that the effects of
aging and stress converge at distinct CpGs to epigenetically up-
regulate FKBP5 in human blood.
FKBP5 Up-Regulation Promotes NF-κB–Related Peripheral Inflammation
and Chemotaxis. To examine potential functional effects of FKBP5
up-regulation in an unbiased manner, we used genome-wide gene
expression data from peripheral blood in the GTP cohort (n =
355) to identify genes that are coregulated with FKBP5. After
FDR correction for multiple comparisons (FDR-adjusted P <
0.05), FKBP5 correlated significantly with a total of 3,275 genes
(Dataset S5). Using these transcripts as input and the unique array
genes expressed above background in blood (except FKBP5) as
reference (9,538 genes), we performed pathway and disease as-
sociation analysis in WebGestalt. The strongest enrichment was
observed for inflammation and was conferred by a total of
123 inflammation-related genes (FDR-adjusted P = 8.1 × 10−6;
Fig. 3A and Dataset S6). Notably, FKBP5 showed robust positive
relation with a host of proinflammatory genes, such as interleukin
and toll-like receptors (Dataset S7). Furthermore, FKBP5 levels
were positively associated with the granulocyte proportion (r =
0.22, P = 5.8 × 10−5) and the granulocyte-to-lymphocyte ratio (r =
0.31, P = 7.4 × 10−9; SI Appendix, Fig. S7), an inflammation
marker that is associated with increased cardiovascular risk and
mortality (44, 45), but not with the proportions of CD4 T cells
(r = −0.05, P = 3.6 × 10−1). These associations suggest that
FKBP5-related inflammation could be driven by enhanced che-
motaxis of granulocytes and other proinflammatory cells. As
plausible mediator of this effect, we focused on interleukin-8 (IL-8),
a major chemokine that recruits and activates granulocytes and
other proinflammatory cells (46). Although FKBP5 down-regulation
has been found to suppress IL-8 production in melanoma cells (19),
no studies have examined whether FKBP5 up-regulation influences
IL-8 secretion by immune cells. To address this possibility, we
overexpressed FKBP5 in Jurkat cells, a human T cell line that
allowed efficient and reproducible transfection with FKBP5
expression vectors (∼3.2-fold induction; Fig. 3B), and measured
their potential to secrete IL-8. FKBP5 overexpression nearly
doubled IL-8 secretion upon immune stimulation (P = 4.4 ×
10−7; Fig. 3C), supporting that increased FKBP5 in T cells could
drive chemotaxis of proinflammatory cells.
To further examine whether the effects of FKBP5 on the
immune system may be driven by distinct transcription factors, we
performed transcription factor target analysis in the GTP cohort
using the same input and reference gene sets (3,275/9,538). The
strongest enrichment was observed for NF-κB (FDR-adjusted
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P = 4.5 × 10−3; Fig. 3A and Dataset S8), a master immune regulator
that has been linked to FKBP5 (13, 17), and this was driven by a
total of 75 NF-κB gene targets (Fig. 3A and Dataset S9). To ex-
perimentally confirm that FKBP5 up-regulation promotes NF-κB
signaling in immune cells, we performed dual-luciferase reporter
assays comparing NF-κB activity between Jurkat cells over-
expressing FKBP5 and cells transfected with control vector. FKBP5
overexpression led to increased NF-κB activity in response to im-
mune stimulation (P = 5.5 × 10−3; Fig. 3D). Together these find-
ings support that FKBP5 up-regulation in immune cells promotes
NF-κB–dependent peripheral inflammation accompanied by the
release of proinflammatory cytokines, such as IL-8. Therefore, our
subsequent analyses sought to better characterize the mechanisms
through which FKBP5 impacts the NF-κB pathway.
Changes in FKBP5 Levels Are Associated with Extensive Alterations in
the NF-κB Coexpression Network. To determine the network-level
effects of FKBP5 deregulation on NF-κB signaling, we used the
gene expression data in the GTP cohort (n = 355) to calculate
the pairwise correlations between genes encoding molecules that
directly interact within the NF-κB pathway, as defined in the
KEGG Pathway Database. These pairwise correlations were
adjusted for the expression levels of all other genes in the
pathway and compared between subjects above vs. below the
median split for FKBP5 expression levels. As shown arithmeti-
cally in Dataset S10 and schematically in Fig. 3E, several partial
pairwise correlations within the NF-κB pathway differed between
the two groups, but the strongest and only significant effect after
multiple test correction was noted for theMAP3K14–CHUK pair
(rlower FKBP5 = 0.13 vs. rhigher FKBP5 = −0.28, FDR-adjusted P =
1.1 × 10−2, permutation P = 2.6 × 10−3). This effect remained
robust after controlling for sex, age, cortisol, and Houseman-
calculated blood cell proportions (FDR-adjusted P = 1.3 × 10−4,
permutation P = 7.1 × 10−3), indicating that the effects of FKBP5
on NF-κB signaling are not confounded by cortisol levels or blood
cell composition.
FKBP5 Up-Regulation Promotes NF-κB Signaling by Strengthening the
Interaction of Key Regulatory Kinases. Since FKBP5 is involved in
scaffolding of regulatory protein complexes, it could enhance
NF-κB signaling by influencing protein–protein interactions be-
tween regulators of the NF-κB pathway. Intriguingly, MAP3K14
and CHUK, the transcript pair most influenced by FKBP5 levels
(Fig. 3E), respectively encode the NF-kappa-B-inducing kinase
(NIK) and the antagonist of nuclear factor kappa-B kinase
subunit alpha (IKKα), two key regulatory kinases of the alter-
native NF-κB pathway. NIK interacts with and phosphorylates
IKKα at serine 176 (pIKKαS176), thereby activating IKKα and
facilitating NF-κB signaling (47, 48).
To examine whether FKBP5 modulates the NIK–IKKα pro-
tein complex, we performed a series of protein–protein binding
experiments in human Jurkat cells and peripheral blood mono-
nuclear cells (PBMC). These experiments showed binding of
FKBP5 with both NIK and IKKα and binding between NIK and
IKKα (Fig. 4A). We then examined whether glucocorticoid
treatment and FKBP5 up-regulation can influence the FKBP5–
NIK–IKKα complex. Both cell types were stimulated with DEX
that robustly induces FKBP5 expression (28, 43). After con-
firming the DEX-induced up-regulation of FKBP5 (∼2.2-fold),
we found that DEX treatment significantly increased the binding
between FKBP5, NIK, and IKKα in both Jurkat cells and PBMC;
this increase was abolished by concomitant treatment with the
selective FKBP5 antagonist SAFit1 (49) in both cell types (Fig. 4
A and B). Accordingly, these effects on protein binding were
accompanied by an increase in pIKKαS176, whereas pIKKαS176
induction was abolished by treatment with SAFit1 (Fig. 4C). This
effect on pIKKαS176 was recapitulated by FKBP5 overexpression
and again blocked by concomitant treatment with SAFit1 in
Jurkat cells (Fig. 4D). Additionally, in this cell line deletion of
the FKBP5 gene with CRISPR/Cas9 abolished the effect of DEX
on pIKKαS176 levels but did not influence vehicle-treated cells
(SI Appendix, Fig. S8), thus mimicking the effects of SAFit1. In
line with these functional effects on the NIK–IKKα complex,
FKBP5 overexpression nearly doubled NF-κB activity in Jurkat
cells, whereas this effect was again prevented by concomitant
treatment with SAFit1 (Fig. 4E). As schematically summarized in
Fig. 4F, these convergent findings show that FKBP5 up-regulation
strengthens NIK–IKKα binding, increases pIKKαS176, and in ef-
fect promotes NF-κB signaling.
NF-κB Signaling Promotes FKBP5 Expression via an NF-κB Response
Element Containing the Age/Stress-Related CpGs. Notably, the
above-identified age/stress-related FKBP5 CpGs flank an NF-κB
response element (SI Appendix, Fig. S9), raising the possibility that
NF-κB signaling could itself modulate FKBP5 expression in im-
mune cells via this site. To address this possibility, we performed
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Fig. 2. Aging and stress-related phenotypes are as-
sociated with epigenetic up-regulation of FKBP5
in peripheral blood in the GTP (n = 355). (A) FKBP5
mRNA levels are negatively associated with aver-
age methylation of the age/stress-related CpGs
(β = −0.3835, SE = 0.1585, P = 1.6 × 10−2). (B and C)
The cortisol–FKBP5 relationship is stronger at lower
methylation levels of the age-related FKBP5 CpGs:
interaction P = 1.4 × 10−3, βcortisol for lower methyl-
ation = 0.0299 (SE = 0.0044) vs. βcortisol for higher
methylation = 0.0069 (SE = 0.0039). The cortisol–
FKBP5 relationship is stronger in older ages: in-
teraction P = 2.4 × 10−5, βcortisol for older subjects =
0.0376 (SE = 0.0050) vs. βcortisol for younger subjects =
0.0075 (SE = 0.0035). (D) Higher levels of depressive
symptoms are associated with stronger cortisol–
FKBP5 relationship in subjects with higher levels of
childhood trauma (cortisol–depression interaction
P = 7.3 × 10−5) but not in subjects with lower levels of
childhood trauma (cortisol–depression interaction
P = 1.4 × 10−1). In all panels, FKBP5 mRNA residuals
are after controlling for all covariates (SI Appendix,
Supplementary Methods).
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dual-luciferase reporter gene assays using a CpG-free vector (50).
We inserted into this vector the FKBP5 sequence that surrounds
the NF-κB response element and includes the two CpG sites of
interest but completely lacks any other CpGs (SI Appendix, Fig.
S9). Immune stimulation induced expression of this reporter
construct in monocyte-derived human cell lines (THP-1) (Fig. 5A),
thus supporting functionality of this response element in immune
cells. Furthermore, in vitro DNA methylation of the age/stress-
related FKBP5 CpGs within this reporter construct resulted in sta-
tistically significant reduction (∼40%) of baseline expression levels
and nearly abolished the induction seen with immune stimulation
(Fig. 5A). To further examine whether these functional effects are
mediated by alterations in NF-κB binding, we used a biotinylated
oligonucleotide-mediated chromatin immunoprecipitation (ChIP)
method (51) (Fig. 5B and SI Appendix, Fig. S9). After confirming
immune stimulation-driven NF-κB binding in THP-1 cells to the
enhancer, in vitro DNA methylation essentially abolished NF-κB
binding to the age/stress-related enhancer site (Fig. 5 C and D).
Together, these findings demonstrate that NF-κB signaling—which,
as we showed above, is promoted by FKBP5 (Figs. 3 and 4)—can in
turn trigger FKBP5 expression in immune cells, thereby forming a
positive feedback loop that can potentiate FKBP5–NF-κB signaling.
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Fig. 3. FKBP5 up-regulation promotes NF-κB–driven peripheral inflammation. (A) FKBP5-related genes in peripheral blood show enrichment for
inflammation-related genes and NF-κB gene targets. The number of genes for each analysis is shown in parentheses. Statistical details are provided in
Datasets S5–S9. (B) Western blotting confirming FKBP5 overexpression in Jurkat T cells transfected with FKBP51-FLAG vs. cells transfected with the control
vector. (C) FKBP5 overexpression nearly doubles IL-8 secretion by Jurkat T cells stimulated overnight with 25 ng/mL of phorbol-12-myristate-13-acetate and
375 ng/mL of ionomycin (PMA/I). The bar graph depicts IL-8 secretion in stimulated cell supernatants measured with ELISA from two independent experiments
(t = 8.8, P = 4.4 × 10−7, n = 8 per condition). For each experiment, fold ratios of IL-8 secretion were calculated relative to stimulated cells expressing the control
vector. IL-8 was not detectable in nonstimulated cells. (D) FKBP5 overexpression increases NF-κB activity in stimulated Jurkat T cells. The bar graph depicts NF-κB
reporter activity in stimulated cells measured with dual-luciferase reporter assays from three independent experiments (t = 3.2, P = 5.5 × 10−3, n = 9 per
condition). For each experiment, fold ratios of NF-κB activity were calculated relative to nonstimulated cells expressing the control vector. (E) FKBP5 ex-
pression changes are associated with extensive alterations in the NF-κB coexpression network in peripheral blood. The circles depict genes encoding molecular
partners of the NF-κB pathway. Continuous lines (edges) represent positive and dotted lines negative pairwise correlations corrected for expression levels of
all other genes in the pathway (details in SI Appendix, Supplementary Methods). Edge widths are proportional to the absolute value of the respective
correlation coefficient. The gene pair with the most robust difference in correlation between the two groups (CHUK-MAP3K14) is highlighted in orange.
Statistical details for all gene pairs are provided in Dataset S10. Error bars depict the SE around the group mean. **P < 10−2; ***P < 10−3.
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This positive feedback can thus be accentuated by decreased
methylation of the NF-κB–responsive FKBP5 enhancer, which can
occur as a consequence of aging and stress.
Age/Stress-Related Decrease in FKBP5 Methylation Is Associated with
a History of Acute MI. Proinflammatory states confer risk for
cardiovascular disease, most notably acute cardiovascular syn-
dromes (52). Thus, the convergent findings presented above,
indicating that lower methylation of the age/stress-related
FKBP5 CpGs up-regulates FKBP5, which in effect promotes
peripheral inflammation, prompted us to examine whether this
lower methylation signature is also associated with higher risk for
acute coronary events. To address this possibility, we used data
on self-reported history of MI that were available in both the
KORA (1,648 subjects without vs. 62 subjects with history of MI)
and the MPIP (310 controls vs. 8 cases) cohorts. Given the small
number of subjects with MI as compared without MI in our
cohorts, we used a statistical approach that resolves case–control
imbalances by calculating and controlling for propensity scores
for the MI assignment (53). After adjustment for all covariates
(SI Appendix, Supplementary Methods), methylation of the age-
related sites was significantly lower in individuals with history of
MI in both cohorts (KORA: β = −0.0535, P = 7.9 × 10−3; MPIP:
β = −0.1992, P = 1.2 × 10−3; Fig. 6A). This association remained
significant after further controlling for education in both the
KORA (P = 4.7 × 10−3) and MPIP (P = 2.6 × 10−5).
Discussion
Aging and stress-related phenotypes are associated with height-
ened inflammation and cardiovascular risk (5, 8–11), but the
underlying molecular mechanisms remain elusive. Here we un-
cover a role for FKBP5 in these relations. As schematically
summarized in Fig. 6B, our findings suggest that aging and stress
synergistically decrease DNA methylation at selected regula-
tory FKBP5 CpGs that moderate the efficiency of an NF-κB–
responsive enhancer. Reduced methylation at this site enhances
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nificant effects were followed with Bonferroni-corrected pairwise comparisons, shown as follows: *P < 5 × 10−2, **P < 10−2, ***P < 10−3, statistically sig-
nificant pairwise comparisons for control vs. DEX or ect. FKBP5; #P < 5 × 10−2, ##P < 10−2, ###P < 10−3, pairwise comparisons for vehicle vs. SAFit1 treatment
(shown only for significant interaction terms of the respective two-way ANOVAs). Error bars depict the SE around the group mean.
Zannas et al. PNAS Latest Articles | 7 of 10
G
EN
ET
IC
S
FKBP5 responses in immune cells, an effect that promotes NF-
κB–driven peripheral inflammation, in part through protein–
protein interactions between FKBP5 and key regulatory kinases of
the NF-κB pathway. NF-κB binding to the FKBP5 enhancer can in
turn stimulate FKBP5 expression, thereby forming a positive
feedback loop of FKBP5–NF-κB signaling that potentially con-
tributes to proinflammatory states and heightened cardiovascular
risk. Finally, we find that both CRISPR/Cas9 deletion of FKBP5
and treatment with a selective FKBP5 antagonist can prevent the
cellular effects of stress and FKBP5 up-regulation on NF-
κB signaling.
By interrogating all 450K-covered FKBP5 CpGs for age-related
changes in DNA methylation, a biological process thought to con-
tribute to disease states (25), we identified two closely juxtaposed
sites at which CpG methylation decreases through an interplay of
aging, early life stress, and depressive symptoms. These findings
were replicated in both individuals of European descent and Af-
rican Americans collectively from seven independent human co-
horts (total n > 3,000) with whole-blood DNA methylation data.
Further analyses in purified blood cells showed that age-related
decrease in FKBP5 methylation occurs in CD4 T cells but not in
neutrophils, suggesting that aging may affect FKBP5 methylation
differentially across immune cell types. Notably, depressive phe-
notypes had consistent effects on FKBP5 methylation in all anal-
yses, whereas the impact of early life stress differed across cohorts,
directly influencing methylation in the HBCS but only moderating
the epigenetic effects of depression in the GTP. This difference
may reflect the more homogeneous stressor as well as the older
and narrower age composition in the HBCS. Despite this differ-
ence, the impact of both early life stress and depression consistently
occurred in the same direction, decreasing FKBP5 methylation in
older ages. Together with previous work (22–24, 26–29), these
findings suggest that the epigenetic influence of environmental
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stress related CpGs (insert sequence shown in SI Appendix, Fig. S9) but
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and transfected into monocyte-derived human cell lines (THP-1). Cells were
then stimulated overnight with 25 ng/mL phorbol-12-myristate-13-acetate
and 375 ng/mL ionomycin (PMA/I), a combination that robustly induces NF-κB
signaling. Data are derived from two independent experiments (n = 12
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with methylation and treatment as factors (F1,44 = 59.5, interaction P < 10
−3),
and statistically significant effects were followed with Bonferroni-corrected
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Fig. 6. Association of age/stress-related FKBP5 decrease in DNA methyl-
ation with a history of MI and overall scheme summarizing study findings.
(A) Age/stress-related decrease in FKBP5 methylation is associated with a
history of MI in two independent cohorts: KORA, n = 1,648 subjects without
vs. 62 with history of MI, βMI = −0.0535, SE = 0.0201, P = 7.9 × 10−3, mean
DNA methylation difference = 1.8% and MPIP, n = 310 subjects without vs.
8 with history of MI, βMI = −0.1992, SE = 0.0611, P = 1.2 × 10−3, mean DNA
methylation difference = 5.3%. The y axis depicts average DNA methylation
levels of the two age/stress-related FKBP5 CpGs (cg20813374 and
cg00130530), after adjusting for all covariates (SI Appendix, Supplementary
Methods). Error bars depict the SE around the group mean. (B) Schematic
summary of study’s findings showing how aging, childhood trauma, and
depressive symptoms interact to decrease FKBP5 methylation at selected
CpGs (cg00130530 and cg20813374) located proximally upstream of the TSS.
These epigenetic changes enhance FKBP5 responses in immune cells, an ef-
fect that in turn promotes NF-κB signaling, whereas this is prevented when
cells are concomitantly treated with selective FKBP5 antagonists. Notably,
NF-κB signaling is not only activated by FKBP5 but it can also trigger FKBP5
transcription through an NF-κB response element that is flanked and mod-
erated by the age/stress-related CpGs. This forms a positive feedback loop of
FKBP5–NF-κB signaling that may be enhanced in individuals with lower
methylation at this site. Enhanced FKBP5 responses and NF-κB activity may in
turn promote chemotaxis of proinflammatory cells and peripheral in-
flammation, potentially contributing to cardiovascular risk.
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exposures and life stress may become more evident as life ad-
vances. Using an in vitro model of replicative senescence, we
further show that replicative aging and stress hormone (gluco-
corticoid) exposure additively decrease methylation at the same
age/stress-related CpGs. Although cellular senescence and gluco-
corticoid exposure in a dish have limitations as models of in vivo
processes, our convergent findings in humans and cells suggest
that aging and stress synergistically influence selected FKBP5
CpGs across different cohorts, distinct cell types, and contexts.
Epigenetic effects involving FKBP5 have been previously
reported to occur in intronic glucocorticoid response elements,
possibly as a result of glucocorticoid receptor binding to the
DNA (26, 28, 54); here we identified lower methylation levels at
two CpGs that include a functional NF-κB response element site
and colocalize with a poised enhancer within 500 bp upstream of
the FKBP5 TSS in most immune cells, including CD4 T cells, the
cell type that shows age-related decrease in FKBP5 methylation.
This functional annotation and our human cohort and in vitro
data together support a model whereby age/stress-related de-
crease in FKBP5 methylation can enhance transcription factor
binding and consequent FKBP5 responses in distinct immune cell
types. The cross-sectional nature of our cohort data precludes
firm conclusions about causal directions, but we speculate that
decreased methylation at the age/stress-related FKBP5 sites may
additively result from the combined effects of cellular aging,
repeated activation of the enhancer, and stress-induced FKBP5
transcription along the human lifespan. Although the overall
effect size of these DNA methylation changes is modest, small
effect sizes in a complex tissue, such as whole blood, likely reflect
the mean of variable effects across distinct cell types. This is
suggested by the larger age-related decrease in FKBP5 methyl-
ation in T cells than neutrophils in the FACS-sorted dataset (SI
Appendix, Fig. S3). Another limitation of the 450K array is its
sparse coverage of CpGs present in the human genome. Future
studies may uncover additional FKBP5 sites of interest by
employing methods that allow more comprehensive coverage,
such as targeted bisulfite sequencing (55).
Through a combination of unbiased network analyses in hu-
man cohorts and mechanistic investigations in immune cells, we
characterized a multilevel positive regulatory feedback between
the stress-responsive cochaperone FKBP5 and the NF-κB sig-
naling cascade. More specifically, FKBP5 was found to exert
pronounced effects on NF-κB–related gene networks and to
promote NF-κB signaling by strengthening the interactions be-
tween NIK and IKKα, two key regulatory kinases of the NF-κB
pathway. These findings are congruent with previous observa-
tions that FKBP5 down-regulation can inhibit NF-κB signaling
(13, 15, 17–19) and show that FKBP5 interacts with NIK and
mediates the glucocorticoid-driven modulation of the NIK–
IKKα regulatory complex in immune cells. Intriguingly, NF-κB
can in turn trigger FKBP5 transcription through an NF-κB re-
sponse element that is flanked and moderated by the age/stress-
related CpGs, thereby forming a positive feedback loop that can
potentiate FKBP5–NF-κB signaling, especially in individuals
with lower methylation at these FKBP5 CpGs. Both CRISPR/
Cas9 deletion of the FKBP5 gene and treatment with the selective
FKBP5 antagonist SAFit1 prevent the cellular effects of stress, as
modeled in vitro by stress hormone treatment, and FKBP5 over-
expression on NF-κB signaling. In contrast, as shown both here
and in a previous study (49), SAFit1 does not influence immune
function under baseline conditions, suggesting that FKBP5 an-
tagonism may represent a pharmacological intervention that―if
targeted at individuals with up-regulated FKBP5―could prevent
some of the unwarranted age/stress-related alterations in immune
function. However, the potential in vivo relevance of the phar-
maceutical modulation of FKBP5–NF-κB signaling will need to be
tested in future studies.
We also find convergent evidence that FKBP5 promotes in-
flammation, a biological process tightly linked with NF-κB
signaling. This effect may in part result from the enhanced
chemotaxis and recruitment of proinflammatory cells, a possi-
bility supported by the positive association of FKBP5 mRNA
levels with the granulocyte-to-lymphocyte ratio and the ability of
FKBP5 to augment immune cell secretion of the major chemo-
kine, and NF-κB target, IL-8 by Jurkat cells, which is a T cell line.
The latter finding extends a previous study showing that FKBP5
down-regulation suppresses NF-κB–mediated production of IL-8
in melanoma cells (19). Both IL-8 levels and the granulocyte-
to-lymphocyte ratio are inflammatory markers associated with
heightened cardiovascular risk and mortality (45, 56, 57). To-
gether these findings suggest that older individuals with higher
stress burden, who show exaggerated FKBP5 responses, are also
more prone to developing heightened inflammation and acute
cardiovascular risk upon stress exposure. This hypothesis is
supported by our observation, in two independent cohorts, that
history of MI is associated with decreased methylation at the age/
stress-related FKBP5 CpGs. FKBP5 up-regulation could thus
represent one molecular link for the known association of de-
pression and early life adversity with heightened inflammation
and cardiovascular risk (3, 4, 6, 58, 59). Nevertheless, the asso-
ciation of MI with decreased FKBP5 methylation should be
interpreted with caution until further validation in larger, in-
dependent studies with more balanced case–control assignment.
Furthermore, mechanistic dissection of the potential role of
FKBP5 in cardiovascular risk will require longitudinal studies
examining the convergent effects of stress and aging in purified
immune cell types.
In conclusion, our findings suggest that aging and stress de-
crease DNA methylation at selected enhancer-related FKBP5
sites, contributing to epigenetic up-regulation of FKBP5 in im-
mune cells, increased NF-κB–driven peripheral inflammation,
and heightened cardiovascular risk. While disease risk is un-
doubtedly shaped by multiple molecular effectors and mecha-
nisms, the present study offers insights by uncovering a
mechanism through which aging and stress confer disease risk at
the molecular level. Such molecular insights may help identify
biomarkers and novel treatment candidates for stress-related
disease and will require orchestrated translational research ef-
forts. Despite these intriguing possibilities, social policies should
always strive to ameliorate or, when possible, prevent excessive
psychosocial stress in the first place.
Materials and Methods
Given space constraints in the main text, selected methods are provided here
and further details can be found in SI Appendix, Supplementary Methods.
The effects of aging and stress-related phenotypes on FKBP5 DNA methyl-
ation were examined in the GTP, KORA, MPIP, and HBCS cohorts (60, 61).
CpG methylation across the FKBP5 locus was measured with the Infinium
HumanMethylation450 BeadChip, and identified CpGs were further vali-
dated with targeted bisulfite sequencing. CpG annotation was performed
with the UCSC Genome Browser and the Roadmap Epigenome Browser.
Genome-wide gene expression data were measured in the GTP using Illu-
mina HumanHT-12 v3 and v4 Expression BeadChips (62). Enrichment analysis
for disease-associated genes and for gene targets of transcription factors
was performed using WebGestalt. For NF-κB coexpression network analyses,
pathway data were derived from the KEGG Pathway Database, and gene
pair correlation coefficients were adjusted using the R package GeneNet.
Cell culture experiments were performed in PBMC from healthy donors, as
well as Jurkat, THP-1, or IMR-90 cell lines. FKBP5 knockout Jurkat cells were
generated using CRISPR/Cas9 plasmids containing gRNA that targets human
FKBP5 and a GFP reporter. The functional effect of DNA methylation at the
age/stress-related FKBP5 site was analyzed with dual-luciferase assays using
a CpG-free luciferase reporter construct (50). Statistical analyses were per-
formed with Sigma Plot version 13.0 (for experimental data) or R version
3.1.0 (for all other data).
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